Mirum prelim 2025 sales ~$520M, above guidance; 2026 outlook $630-650M; acquiring Bluejay for HDV

Mirum Pharmaceuticals, Inc.

2025-FY EPS reported -$0.47 revenue$521,312,000

Preliminary 2025 net product sales ~$520M, exceeding upper end of guidance.
2026 guidance: global net sales $630M-$650M; positive cash flow from operations in 2025.
LIVMARLI 2025 sales ~$359M (US $243M, +69% YoY); CHOLBAM/CTEXLI ~$161M (+31% YoY).
Proposed acquisition of Bluejay Therapeutics (brelovitug for HDV) expected close late Jan 2026; $268.5M private placements.
Pipeline: volixibat PSC topline Q2 2026; LIVMARLI EXPAND topline Q4 2026; HDV AZURE data H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.